• LAST PRICE
    15.1100
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    6.0600/ 1
  • Ask / Lots
    24.0200/ 1
  • Open / Previous Close
    0.0000 / 15.1100
  • Day Range
    ---
  • 52 Week Range
    Low 10.3800
    High 20.6700
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 16
TimeVolumeTYRA
09:32 ET19515.72
09:34 ET10016.15
09:38 ET20815.57
09:43 ET20015.54
09:45 ET20015.61
09:48 ET10015.62
09:50 ET79315.475
09:52 ET10015.6
09:54 ET50015.4
09:56 ET41215.42
09:59 ET20015.23
10:03 ET30015.02
10:08 ET100015.18
10:10 ET10015.29
10:14 ET10015.515
10:17 ET45215.52
10:21 ET10015.5
10:28 ET47115.505
10:30 ET39115.47
10:33 ET70015.45
10:35 ET10015.44
10:37 ET130015.36
10:39 ET30015.33
10:42 ET20015.285
10:46 ET70015.205
10:48 ET20015.2
10:50 ET20015.24
10:51 ET20015.2
10:53 ET790015.1
10:57 ET83015.155
11:00 ET282215.09
11:04 ET50015.04
11:06 ET41415.03
11:09 ET10014.97
11:11 ET60014.935
11:13 ET10014.99
11:15 ET40014.91
11:18 ET30014.79
11:20 ET50014.84
11:24 ET40014.95
11:26 ET30014.89
11:27 ET10014.92
11:29 ET40014.83
11:31 ET170014.945
11:33 ET10015.015
11:36 ET50014.95
11:38 ET30014.995
11:40 ET10014.95
11:44 ET50014.925
11:45 ET20014.925
11:47 ET10014.89
11:49 ET10014.89
11:54 ET30014.89
11:56 ET50014.935
11:58 ET20014.89
12:00 ET30014.9
12:02 ET20014.94
12:05 ET120015.02
12:09 ET50015.075
12:12 ET40015.01
12:14 ET13415.075
12:16 ET50015
12:18 ET40014.99
12:20 ET30015.03
12:23 ET10014.99
12:25 ET20014.92
12:27 ET30014.89
12:32 ET10014.86
12:34 ET30014.83
12:38 ET10014.82
12:39 ET10014.82
12:41 ET10014.8
12:43 ET90014.89
12:45 ET10014.865
12:48 ET35114.91
12:52 ET10014.92
12:54 ET20014.85
12:56 ET10014.82
12:59 ET70314.84
01:01 ET40014.9
01:03 ET10014.86
01:06 ET10014.87
01:08 ET100014.88
01:10 ET30014.89
01:12 ET20014.89
01:14 ET20014.86
01:15 ET20014.87
01:17 ET30014.88
01:19 ET10014.895
01:21 ET20014.84
01:24 ET20014.8
01:26 ET80014.855
01:28 ET10014.9
01:33 ET80214.9
01:37 ET30014.915
01:39 ET10014.91
01:42 ET20314.96
01:44 ET10014.975
01:46 ET110015.05
01:50 ET10015.075
01:51 ET34615.03
01:53 ET30015.03
02:00 ET40014.97
02:02 ET30014.97
02:06 ET29814.89
02:08 ET20514.89
02:09 ET20014.9
02:11 ET20014.895
02:13 ET114414.96
02:26 ET60014.97
02:29 ET40014.965
02:38 ET20015.04
02:42 ET10015.015
02:45 ET10015.025
02:51 ET10015.02
02:58 ET400015.055
03:00 ET50015.06
03:07 ET30015.0125
03:12 ET40015.04
03:14 ET10015.065
03:16 ET30015.04
03:21 ET20015
03:23 ET10015.05
03:25 ET50015.02
03:27 ET71615.05
03:30 ET43215.02
03:34 ET20015.025
03:36 ET10015.015
03:38 ET30015.02
03:39 ET30015.02
03:41 ET20015.015
03:43 ET60015.05
03:45 ET40015.02
03:48 ET40015.06
03:50 ET40015.12
03:52 ET30015.14
03:54 ET1121615.15
03:56 ET311415.155
03:57 ET176815.115
03:59 ET196415.11
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesTYRA
Tyra Biosciences Inc
793.6M
-9.3x
---
United StatesVRDN
Viridian Therapeutics Inc
797.1M
-2.4x
---
United StatesETNB
89Bio Inc
785.6M
-4.1x
---
United StatesELVN
Enliven Therapeutics Inc
783.7M
-7.7x
---
United StatesSPRY
ARS Pharmaceuticals Inc
780.7M
-14.1x
---
United StatesZNTL
Zentalis Pharmaceuticals Inc
779.5M
-2.4x
---
As of 2024-04-26

Company Information

Tyra Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. Its initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. Its lead product candidate, TYRA-300, is an investigational, oral, FGFR3-selective inhibitor being evaluated in an international, multi-center, open label Phase 1 clinical study, SURF301. Its second oncology product candidate, TYRA-200, is an investigational, oral, FGFR1/2/3 inhibitor with potency against activating FGFR2 gene alterations, and clinically important molecular brake and gatekeeper resistance mutations.

Contact Information

Headquarters
2656 State StreetCARLSBAD, CA, United States 92008
Phone
619-728-4760
Fax
302-655-5049

Executives

Non-Executive Chairman of the Board
Robert More
President, Chief Executive Officer, Treasurer, Director
Todd Harris
Chief Financial Officer
Alan Fuhrman
Chief Operating Officer
Daniel Bensen
General Counsel, Company Secretary
Ali Fawaz

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$793.6M
Revenue (TTM)
$0.00
Shares Outstanding
52.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.62
Book Value
$4.75
P/E Ratio
-9.3x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.